Clinical Trials

If you are interested in any of the trials or think that you meet the criteria to participate, please call the Presence Cancer Care at 815-730-3098.


ISO-CC-007: 1st-line Metastatic Colorectal
A randomized, multi-center, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer


Relapsed/Refractory Hodgkin Lymphoma – E4412
A Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma



EA6134 : First-Line Metastatic Melanoma
A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma


EAA173: 1st-line high risk Smoldering Multiple Myeloma
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma


EA8153 : 2nd line Metastatic Prostate
Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial


Connect AZA-MDS-006 : AML and MDS Registry
The Connect MDS and AML Disease Registry is a prospective, longitudinal, multi-center observational cohort study of patients with newly diagnosed MDS or AML Study


NCT 02193282 CTSU/A151216 : NSCLC
Adjuvant Lung Cancer Enrichment Marker Identification & Sequencing Trial (ALCHEMIST)
EA5163 : Advanced Nonsquamous NSCLC
A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non‐Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature‐driven Analysis
ANAM 17-20 : Weightloss in NSCLC
A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC)
AB154CSP0002: First-Line Metastatic Squamous or NonSquamous NSCLC w/ PD-L1 >50%
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122 and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer


A031704 - 1st-line Metastatic Renal Cell
PD-inhibitor (Nivolumab) and Ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab in metastatic untreated Renal Cell Cancer


Collection and Distribution of Biofluids and Tumor Tissue Biospecimens for Research Purposes - IPROCESS-BSG-001-US Advarra IRB 1/14/2019 - Bluestar Genomics
Untreated - Bladder, Brain, Breast, Cervical, Colorectal, Esophageal, Gastric, Kidney, Liver, Lung, Ovarian, Pancreatic, Prostate, Uterine and AML
Exact Sciences 2018-01 : Biomarkers on Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors: Breast, Lung, Coorectal, Prostate, Bladder, Uterine, Kidney/Renal Pelvis, Pancreatic, Liver, Stomach, Ovarian or Esophageal
S1815 CIRB: First-Line Biliary Tract Cancers
A Phase III Randomized Trial Of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed Advanced Biliary Tract Cancers
EA2186: Geriatric Metastatic Pancreatic
A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer


NRG- BR003 NCT 02488967 : Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjudavant Therapy Comparing Doxorubib Plus Cyclophosphanide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
NRG- BR004 : First-line HER2+ Metastatic Breast
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
S1418 : Adjuvant Breast Triple Negative
A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with = 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
EA1181: First-Line Stage II and IIIa HER2+ prior to TX Breast Cancer
§ (Compass HER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response


1st-line Locally Advanced/Metastatic Urothelial Cancer – MK7902-011
A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Matching Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)

Our Team


Medical Director of Clinical Research

Dr. Nafisa Burhani, MD

Manager of Clinical Research

Karen Sceniak, CCRC

Clinical Research Coordinators


Data Manager


Regulatory Affairs Manager